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Statins, 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors,
have been found to provide protective effects against several bacterial infectious
diseases. Although the use of statins has been shown to enhance antimicrobial
treated Helicobacter pylori eradication and reduce H. pylori-mediated inflammation, the
mechanisms underlying these effects remain unclear. In this study, in vitro and ex vivo
macrophage models were established to investigate the molecular pathways involved
in statin-mediated inhibition of H. pylori-induced inflammation. Our study showed that
statin treatment resulted in a dose-dependent decrease in intracellular H. pylori burden in
both RAW264.7 macrophage cells and murine peritoneal exudate macrophages (PEMs).
Furthermore, statin yielded enhanced early endosome maturation and subsequent
activation of the autophagy pathway, which promotes lysosomal fusion resulting in
degradation of sequestered bacteria, and in turn attenuates interleukin (IL)-1β production.
These results indicate that statin not only reduces cellular cholesterol but also decreases
the H. pylori burden in macrophages by promoting autophagy, consequently alleviating
H. pylori-induced inflammation.
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INTRODUCTION
Helicobacter pylori is a Gram-negative microaerophilic spirochete that colonizes the human
stomach and is estimated to have infected greater than half of the global population (Marshall,
2002). Persistent H. pylori infection is associated with several upper gastrointestinal disorders such
as gastritis, peptic ulcers, and gastric adenocarcinoma (Wroblewski et al., 2010).
Although H. pylori is generally considered an intracellular pathogen, this organism lives in
the mucosal layer and tightly adheres to the gastric epithelial surface. Notably, virulent strains
of H. pylori, can delay uptake and promote the formation of megasomes within macrophages,
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which comprises a crucial feature of H. pylori-induced
pathogenesis (Allen et al., 2000). Moreover, cholesterol-
α-glucosyltransferase, which is responsible for cholesterol
glucosylation in macrophages, was found to contribute to
the protection of H. pylori from phagocytosis (Wunder et al.,
2006). These lines of evidence suggest that H. pylori can survive
intracellularly within specific compartments of macrophages to
avoid phagocytosis-mediated killing.
The inhibitors of 3-hydroxy-3-methyl-glutaryl-coenzyme A
(HMG-CoA) reductase, commonly known as statins, are widely
prescribed for lowering serum cholesterol (Armitage, 2007).
Notably, statins have also been shown to reduce the risk of
severe bacterial infections, including infections by Chlamydia
pneumoniae (Erkkilä et al., 2005), Clostridium difficile (Motzkus-
Feagans et al., 2012), Staphylococcus aureus (Chow et al., 2010),
and Streptococcus pneumoniae (Boyd et al., 2012). However, the
immunomodulatory properties of statins provide only a partial
explanation for the mechanism by which these compounds
inhibit bacterial infections (Jain and Ridker, 2005).
The human immune system employs various mechanisms to
inhibit bacterial infections. While autophagy is a cell process
that typically functions as a recycling pathway, degrading
nonfunctional and unnecessary components and rearranging
these components to support cellular survival (Mariño et al.,
2014), this process was also found to contribute to immune
defense by degrading invading pathogens (Mizushima et al.,
2008; Zhao et al., 2008). As such, these findings indicate that
stimulation of cellular autophagy may attenuate H. pylori-
induced pathogenesis (Yang and Chien, 2009).
Antimicrobial agents, particularly a triple therapy regimen
consisting of a proton-pump inhibitor, amoxicillin, and
clarithromycin, are the most effective means of eradicating H.
pylori infections (O’Connor et al., 2013). Although the cure rate
varies between countries, the triple therapy regimen remains the
recommended treatment forH. pylori infection (O’Connor et al.,
2013). Notably, the administration of this triple therapy regimen
along with statins has been shown to accelerate the clearance
of H. pylori and reduce H. pylori-related inflammation (Tariq
et al., 2007; Yamato et al., 2007; Nseir et al., 2012). However,
the molecular mechanisms underlying the regulatory effects
of statins on H. pylori-induced pathogenesis require further
investigation. In this study, we first hypothesized that statins may
influence the immune response via upregulation of autophagy
and attenuation of H. pylori-induced inflammation. We utilized
in vitro and ex vivo macrophage models of H. pylori infection
to investigate the mechanism underlying the statin-mediated
mitigation of H. pylori pathogenesis. We also explored how
statin influences the bacterial burden and reduces inflammation
by upregulating cellular autophagy and consequently alleviating
H. pylori-associated pathogenesis.
MATERIALS AND METHODS
Antibodies and Reagents
The light chain 3 (LC3)-specific monoclonal antibody was
purchased from Cell Signaling Technology (Danvers, MA),
while the rabbit antibodies against SQSTM1/p62 and beclin-1
were purchased from GeneTex (Irvine, CA). The rabbit anti-
early endosome antigen-1 (EEA-1), anti-lysosome-associated
membrane protein-1 (LAMP-1), and mouse monoclonal anti-
β-actin antibodies were purchased from Abcam (Cambridge,
UK), Abgent (San Diego, CA), and Santa Cruz Biotechnology
(Dallas, TX), respectively. Simvastatin was purchased from
Sigma-Aldrich (St. Louis, MO).
Bacterial and Cell Culture
H. pylori 26695 (ATCC 700392) was cultured on 10% sheep
blood agar plates in a microaerophilic environment (10% CO2,
5% O2, and 85% N2) at 37
◦C. Cultures were incubated for 24–
36 h to achieve optimum microbial activity (Lai et al., 2005).
Murine RAW264.7 macrophages (ATCC TIB-71) were cultured
in Dulbecco’s Modified Eagle Medium (DMEM) supplemented
with 10% endotoxin-free fetal bovine serum (HyClone, Logan,
UT).
Analysis of Cellular Cholesterol and
Cytotoxicity
RAW264.7 cells were treated with simvastatin (0, 5, or 10µM)
at 37◦C for 24 h. Untreated cells were utilized as a control. The
cellular cholesterol content of each treatment group was then
evaluated using an Amplex Red cholesterol assay kit (Molecular
Probes, Carlsbad, CA). The percentage of cellular cholesterol was
determined as follows: (fluorescence of treated cells obtained
from a standard curve/total fluorescence of untreated cells)
× 100%. Meanwhile, the viability of RAW264.7 cells was
determined via the trypan blue exclusion assay, as described
previously (Lai et al., 2008).
Preparation of Murine Peritoneal Exudate
Macrophages (PEMs)
PEMs isolated from C57BL/6 mice were used to investigate the
effects of simvastatin onH. pylori-induced autophagy. Mice were
maintained at the Animal Center of Chang Gung University
(Taoyuan, Taiwan). All procedures were performed according
to the “Guide for the Care and Use of Laboratory Animals”
(NRC, USA) and were approved by the Animal Experimental
Committee of Chang Gung University. PEMs were prepared after
euthanasia by lavaging mice with an intraperitoneal injection
of 3% thioglycolate, as described previously (Lu et al., 2012a).
Harvested cells were then seeded into 24-well tissue culture plates
and incubated at 37◦C for 2 h, after which non-adherent cells
were removed. Adherent cells were then treated with simvastatin
and/or H. pylori and subjected to bacterial intracellular survival
assay and western blot analyses.
Phagocytosis Assay
RAW264.7 cells were treated with PBS or simvastatin (0, 5,
or 10µM) for 8 h and incubated with latex beads (IgG-FITC
complex) at a ratio of 1:100, according to the manufacturer’s
instructions (Cayman, Ann Arbor, MI). After incubation for
1 h, the treated cells were washed with PBS, fixed in 3.7%
paraformaldehyde, and then subjected to flow cytometry analysis.
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Bacterial Adhesion Assay
The numbers of cell-associated bacteria were measured as
described previously (Lai et al., 2008). Briefly, RAW264.7 cells
were treated with PBS or 10µM simvastatin for 8 h and then
infected with H. pylori at a multiplicity of infection (MOI) of
100 for 6 h. Infected cells were washed three times to remove
unbound bacteria and then lysed with distilled water for 10 min.
Lysates were diluted in PBS, then plated onto Brucella blood agar
plates and cultured for 3–5 days. Viable bacteria were counted
and expressed as colony-forming units (CFU).
Bacterial Intracellular Survival Assay
RAW264.7 cells and murine PEMs and cells were not treated
or treated with 10µM simvastatin for 8 h and then infected
with H. pylori (MOI = 100) for 16 h. Cells were treated with
gentamycin (100µg/ml) to eradicate the extracellular bacteria
(Lai et al., 2006). The H. pylori-infected cells were washed with
PBS three times and then incubated in sterile water at 37◦C for
10min to osmotically disrupt the cell membrane. The resulting
lysates were then diluted in PBS and applied to Brucella blood
agar plates. Viable H. pylori colonies were enumerated after 3–5
days of incubation and were presented as CFU.
Western Blot Analysis
To analyze protein expression levels, RAW264.7 cells or PEMs
were treated with simvastatin (0, 5, or 10µM) at 37◦C for
8 h prior to infection with H. pylori for 16 h. Cell lysates were
prepared and boiled with sample dye at 100◦C for 5min.
Samples were separated by 10–12% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred
to polyvinylidene fluoride membranes (Millipore, Billerica, MA).
Membranes were blocked by incubation in TBS-T (Tris-buffered
saline containing 0.1% Tween 20) containing 5% skim milk
at room temperature for 1.5 h, and then probed with primary
antibodies specific to autophagy-related proteins or β-actin
(0.2µg/ml), respectively, at 4◦C overnight. Probed membranes
were washed with TBS-T and incubated with horseradish
peroxidase-conjugated secondary antibodies (0.1µg/ml) (Santa
Cruz Biotechnology) at room temperature for 1 h, and proteins
of interests were visualized using ECLTM western blotting
Detection Reagents (GE Healthcare, Little Chalfont, UK), and
an ImageQuant LAS-4000 system (GE Healthcare). Protein
expression levels were quantified using UN-SCAN-IT gel 6.1
software (Silk Scientific Corporation, Orem, UT).
Immunofluorescence Microscopy
To visualize the co-localization of autophagosome fused
with lysosome, cells were subjected to immunofluorescence
microscopy analysis (Parihar et al., 2014). RAW264.7 cells (2
× 106) were seeded on cover glass in 6-well plates, treated
with 10µM simvastatin, and co-incubated with H. pylori (MOI
= 100) for 16 h. To observe the early to late stages of
autophagosome formation, the cells were probed using a Cyto-
IDTM autophagy detection kit (Enzo Life Sciences, Villeurbanne,
France; Chan et al., 2012). Meanwhile, the formation of lysosome
was observed using a Cell NavigatorTM Lysosome Staining Kit
(AAT Bioquest, Sunnyvale, CA). Fluorescence signals from H.
pylori-infected macrophages were visualized by confocal laser-
scanning microscopy (Zeiss LSM 780; Carl Zeiss, Oberkochen,
Germany).
Enzyme-Linked Immunosorbent Assay
(ELISA)
After treating with 10µM simvastatin and infecting with
H. pylori, RAW264.7 cell supernatants were collected and
interleukin (IL)-1β secretion was analyzed using a mouse IL-
1β ELISA kit, according to the manufacturer’s instructions
(Invitrogen, Waltham, MA).
Statistical Analysis
Experimental results are expressed as means ± standard errors
of the mean (SEM). Differences in results between groups were
evaluated using Student’s t-tests. For analyses of variance, one-
way analysis of variance (ANOVA) was utilized. P < 0.01
were considered statistically significant. Statistical analyses were
performed using SPSS version 11.0 software (SPSS Statistics, Inc.,
Chicago, IL).
RESULTS
Statin Reduces the Intracellular Burden of
H. pylori in Macrophages
Statins are known as inhibitors of HMG-CoA reductase, which is
the rate-limiting enzyme of the mevalonate pathway (Armitage,
2007). In this study, we first evaluated whether simvastatin is
capable of reducing the cellular cholesterol of macrophages.
As shown in Figure 1A, there was a dose-dependent reduction
in the level of cellular cholesterol in RAW264.7 macrophage
cells treated with simvastatin (Figure 1A). We then assessed
whether simvastatin treatment affected macrophage or bacterial
viability. Notably, both macrophages and H. pylori remained
viable, even after treatment with 10µM simvastatin (Figure 1B).
These results indicate that simvastatin reduces the levels of
cellular cholesterol in macrophages without affecting cell viability
or bacterial survival.
To further validate whether statin-treated macrophages
function similarly to untreated macrophages, RAW264.7
cells were untreated or treated with statin (10µM) and
subjecting to the latex bead phagocytosis assay. As shown in
Figure S1, macrophages treated with statin exhibited similar
levels of phagocytosis to the untreated cells. Likewise, statin
treatment had no significant effect on extracellular bacterial
adhesion (Figure S2). Together, these results demonstrate that
macrophages retain their normal functions in the presence of
statins.
To investigate whether simvastatin inhibits H. pylori
survival in macrophages, RAW264.7 cells were pretreated with
simvastatin for 8 h and infected with H. pylori (MOI = 100) for
an additional 16 h. As shown in Figure 1C, treatment with 5
and 10µM simvastatin resulted in significant dose-dependent
reductions in H. pylori burden in RAW264.7 cells. To further
explore the inhibitory effects of simvastatin on intracellular
bacterial survival, we performed an ex vivo analysis using murine
PEMs isolated from C57BL/6 mice. As observed in RAW264.7
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FIGURE 1 | Statin treatment reduces cellular cholesterol and decreases the intracellular bacterial burden in macrophages. (A) RAW264.7 cells were
treated with various concentrations of simvastatin (0, 5, or 10µM) for 24 h and subjected to cellular cholesterol assay analysis. (B) RAW264.7 and Helicobacter pylori
cultures were treated with 0, 5, or 10µM simvastatin for 24 h. Macrophage cell viability was then assessed by trypan blue exclusion assay analysis and bacterial
viability was determined by counting the number of colony-forming units (CFU) for each treatment group on blood agar plates. (C) RAW264.7 cells and (D) murine
peritoneal exudate macrophages (PEMs) were pretreated with simvastatin (0, 5, or 10µM) for 8 h and infected with H. pylori at a MOI of 100 for 16 h. The numbers of
viable intracellular bacteria were then determined via gentamicin protection assays and were expressed as the number of viable CFU. Statistical significance was
evaluated using Student’s t-test. *P < 0.01.
cells, PEMs that were pretreated with 5 or 10µM simvastatin for
8 h exhibited significant reductions in H. pylori burden after 16 h
of infection compared to the control population (Figure 1D).
These results demonstrate that simvastatin decreases the
intracellular H. pylori burden in both in RAW264.7 and primary
murine PEMs in a dose-dependent manner.
Statin Promotes H. Pylori-Induced
Autophagy in Macrophages
Because treatment of cells with cholesterol-lowering agents
has been shown to induce autophagy (Cheng et al., 2006; de
Chastellier and Thilo, 2006), we investigated whether statin
influences the immune response by upregulating autophagy and
attenuating H. pylori-induced inflammation. To address this
question, we established amacrophage infectionmodel to explore
the mechanisms involved in the inhibition of H. pylori-induced
inflammation by statin. Following the induction of autophagy,
the microtubule-associated protein LC3 is converted from LC3-
I to LC3-II. As such, the expression of LC3-II is considered
a marker of autophagy (Klionsky et al., 2012). We therefore
evaluated the expression levels of this protein, as well as those
of EEA-1, an early marker localized on phagosomal membranes,
and LAMP-1, a marker localized on lysosomal membranes (Fratti
et al., 2001; Huynh et al., 2007; Parihar et al., 2014), in RAW264.7
cells infected with H. pylori for 0–48 h by western blot analysis.
As shown in Figure 2A, there was a gradual increase in the
levels of H. pylori-induced EEA-1 and LAMP-1 expression, and
a concurrent increase in the conversion of LC3-I to LC3-II, over
the course of the infection. Peak levels of conversion from LC3-I
to LC3-II were observed between 16 and 36 h. Next, we evaluated
the expression of the autophagy-related proteins beclin-1 and
SQSTM1/p62, which are known to participate in the initiation
of autophagy with LC3-II (Kang et al., 2011; Levine et al., 2011).
RAW264.7 cells treated with simvastatin (0, 5, or 10µM) and
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infected with H. pylori for 16 h exhibited slightly increased
expression of beclin-1 and p62 (Figure 2B). To confirm these
findings, we subsequently analyzed the effects of simvastatin on
PEMs isolated from C57BL/6 mice. As shown in Figure 2C, we
observed increased levels in the conversion of LC3-I to LC3-II,
as well as increased expression of beclin-1 and p62, in H. pylori-
infected PEMs treated with simvastatin, compared to untreated
cells. These results suggest that simvastatin treatment not only
reduces cellular cholesterol but also promotes H. pylori-induced
autophagy in macrophages.
Statin Facilitates Autophagosome
Formation in H. pylori-Infected
Macrophages
To further evaluate the effects of simvastatin on macrophages,
RAW264.7 cells were stained with Cyto-ID autophagy green
dye for visualization of autophagosomes and examined by
confocal microscopy. The control group (untreated and
uninfected) exhibited faint Cyto-ID green fluorescence (puncta-
formation; Figure 3A), while cells treated with simvastatin or
H. pylori alone showed only moderate staining. In contrast,
cells that were treated with simvastatin and subsequently
infected with H. pylori exhibited significantly increased
autophagosome formation compared to both the control
group and to the cells treated with simvastatin or H. pylori
alone (Figure 3B). These results demonstrate that simvastatin
enhances H. pylori-induced autophagosome formation in
macrophages.
Statin Promotes Autophagosome and
Lysosome Fusion in H. pylori-Infected
Macrophages
Mature autophagosomes fuse with lysosomes to form
autolysosomes, which contain lysosomal enzymes capable
of degrading sequestered bacteria (Deen et al., 2013). We
thus investigated whether statin treatment promotes bacterial
degradation in macrophages by inducing autophagosome
maturation and fusion with lysosomes. As shown in Figure 4A,
RAW264.7 cells treated with either simvastatin or H. pylori
alone exhibited little co-localization of Cyto-ID and lysosomal
fluorescence within the cytoplasm. Conversely, cells treated with
simvastatin and then infected with H. pylori exhibited marked
co-localization of Cyto-ID and lysosomes (Figure 4B). We also
tested whether statin treatment promoted H. pylori-induced
lysosome formation. As shown in Figure 5A, treatment with
both simvastatin andH. pylori resulted in increases in EEA-1 and
LAMP-1 expression, compared with cells exposed to simvastatin
or H. pylori alone. We then sought to analyze whether statin
reduces the bacterial burden, and whether this had any effect
on IL-1β production. The induction of IL-1β was dramatically
increased in cells infected with H. pylori alone (Figure 5B). In
contrast, when cells were treated with 10 µM simvastatin and
then infected with H. pylori, there was a significant decrease in
the IL-1β secretion compared with the cells exposed to H. pylori.
Collectively, our results reveal that statin treatment facilitated
H. pylori-induced autophagy, and subsequently promoted
FIGURE 2 | Statin increases Helicobacter pylori-induced autophagy in
macrophages. (A) RAW264.7 cells were infected with H. pylori at a MOI of
100 for the indicated times (0, 2, 6 16, 36, and 48 h). The expression levels of
proteins were then evaluated by western blot analysis. (B) RAW264.7 cells and
(C) peritoneal exudate macrophages (PEMs) were pretreated with simvastatin
(0, 5, or 10µM) for 8 h and then infected with H. pylori at a MOI of 100 for an
additional 16 h. Cell lysates were then prepared and subjected to western blot
analysis for detection of autophagy-associated proteins. β-actin expression
levels were used as the protein loading control. Representative western blot
results from one of two independent experiments are shown. The expression
level of each protein was quantified by analysis of signal intensity, and
normalized with that of β-actin. The expression level of each respective protein,
relative to that of the control group, is indicated at the bottom of each lane.
autophagosome maturation and fusion with lysosomes, thereby
reducing the bacterial burden in macrophages and ameliorating
the inflammatory response.
DISCUSSION
Cholesterol-enriched microdomains, which provide platforms
for microbial infection, are thought to be associated with
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FIGURE 3 | Statin enhances autophagosome formation in Helicobacter pylori-infected macrophages. (A) Untreated RAW264.7 cells and cells treated with
10µM simvastatin were infected with or without H. pylori at a MOI of 100. After incubation for 16 h, the cells were fixed and stained with Cyto-ID and Hoechst 33342
for detection of autophagosomes (green) and visualization of nuclei (blue), respectively. Stained cells were analyzed by confocal microscopy. Scale bar, 5µm. (B) Box
plots summarizing the number of Cyto-ID puncta in each cell (50 cells were evaluated per sample). Statistical significance was evaluated using Student’s t-test. *P <
0.01.
various infectious bacterial and viral diseases (Lin et al.,
2015). In particular, cholesterol plays a crucial role in H.
pylori cell invasion and virulence (Lai et al., 2013). Depletion
of cellular cholesterol not only attenuates H. pylori-induced
pathogenesis (Hutton et al., 2010; Lai et al., 2011) but also
promotes autophagy (Cheng et al., 2006), which has been
shown to contribute to immune defense against invading
pathogens (Levine et al., 2011; Deretic et al., 2013; Lai
et al., 2015). Statins, inhibitors of HMG-CoA reductase that
are widely prescribed for lowering serum cholesterol, have
also been employed to reduce the risk of certain bacterial
infections (Chow et al., 2010; Nseir et al., 2010; Boyd et al.,
2012; Motzkus-Feagans et al., 2012). The in vitro and ex
vivo approaches utilized in this study provided evidence
that statin treatment results in reduced bacterial burden
in macrophages, and consequently attenuation of H. pylori
pathogenesis, via activation of autophagy. These findings
suggest that such cholesterol modulation could comprise a
novel therapeutic approach for controlling H. pylori-associated
diseases.
Previous studies have shown that H. pylori actively delays
its uptake by macrophages, inhibits phagosome maturation
via a VacA and urease-dependent mechanism, and resides in
large vacuoles called megasomes (Allen et al., 2000; Schwartz
and Allen, 2006). Another unusual feature of H. pylori is a
requirement for cholesterol, which is acquired from host cell
membranes and incorporated into the bacterium as cholesteryl
glucosides (Wunder et al., 2006). In addition, it has been reported
that H. pylori encodes several virulence factors that exploit
cholesterol to gain a foothold in the host niche (Murata-Kamiya
et al., 2010; Lai et al., 2013).Meanwhile, surfacemolecules located
within the cholesterol-rich microdomains of host cells sense and
respond to H. pylori in an orchestrated manner (Lu et al., 2012b;
Lin et al., 2016). As such, both host- and pathogen-derived factors
play critical roles in disease progression. In previous studies,
we demonstrated that reduced cellular cholesterol resulted in
reduced VacA activity, as well as attenuated CagA-induced
inflammation and decreased bacterial survival, in H. pylori-
infected gastric epithelial cells (Lai et al., 2008, 2011; Wang
et al., 2012). Specifically, reductions in cholesterol disrupt
the integrity of lipid rafts, resulting in decreased type IV
secretion system-mediated translocation of CagA into host
cells (Hutton et al., 2010), thereby reducing downstream
signaling and attenuating the inflammatory response (Lai
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 6 January 2017 | Volume 6 | Article 203
Liao et al. Statin Reduces H. pylori Burden in Macrophages
FIGURE 4 | Statin facilitates the fusion of autophagosomes and lysosomes in Helicobacter pylori-infected macrophages. (A) Untreated RAW264.7 cells
and cells treated with 10µM simvastatin were infected with or without H. pylori at a MOI of 100 for 16 h. Cells were then fixed, stained with Cyto-ID (green), Lysosome
Staining (red), and Hoechst 33342 (blue) for visualization of autophagosomes, lysosomes, and nuclei, respectively, and analyzed by confocal microscopy. Scale bar,
5µm. (B) Box plots summarizing the numbers of co-localized Cyto-ID puncta and lysosomes in each cell (50 cells were evaluated per sample). Statistical significance
was evaluated using Student’s t-test. *P < 0.01.
FIGURE 5 | Statin induces lysosome formation and mitigates proinflammatory cytokine production in Helicobacter pylori-infected macrophages.
RAW264.7 cells were treated with 10µM simvastatin for 8 h and then infected with H. pylori at a MOI of 100 for an additional 16 h. (A) The expression levels of EEA-1
and LAMP-1 were analyzed by western blot. Representative western blot results from one of two independent experiments are shown. The expression level of each
protein was quantified by analysis of signal intensity, and normalized to that of β-actin. The expression level of each respective protein, relative to that of the control
group, is indicated at the bottom of each lane. (B) The levels of IL-1β present in each culture supernatant were determined by enzyme-linked immunosorbent assay
(ELISA). Statistical significance was evaluated using Student’s t-test. *P < 0.01.
et al., 2011). In the current study, we demonstrate that
statin treatment yielded enhanced autophagy and reduced
bacterial burdens in macrophages, followed by decreased levels
of H. pylori-induced IL-1β production, suggesting that statin
may attenuate H. pylori-induced pathogenesis via multiple
mechanisms.
Autophagy is a process involving the degradation and
recycling of intracellular components to provide cellular energy
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and maintain nutritional support for cell survival (Singh and
Cuervo, 2011). Previous studies reported that H. pylori infection
induces autophagosome formation, and that autophagic vesicles
provide special niches for H. pylorimultiplication in both gastric
epithelial cells (Terebiznik et al., 2009) and macrophages (Wang
et al., 2009). AlthoughH. pyloriwas protected in autophagosomes
during the early stages of infection, the bacteria were degraded
within the resulting autolysosomes of both cell types after 24 h
of infection (Chu et al., 2010; Wang et al., 2010). Consistent with
these findings, peripheral blood monocytes (PBMCs) harboring
a single nucleotide polymorphism within the coding sequence
for Autophagy Related 16-Like 1 (ATG16L1; ATG16L1300A),
which is essential for autophagosome formation, exhibited
impaired autophagy and increased susceptibility to H. pylori
infection (Raju et al., 2012). In contrast, PBMCs harboring the
ATG16L1300T allele showed a superior autophagic response and
exhibited increased H. pylori clearance compared with PBMCs
carrying the 300A allele. These data imply that induction of
autophagy might comprise a general mechanism for restricting
bacterial replication in phagocytes (Deen et al., 2013).
In addition to lowering cellular cholesterol, statins were
found to play a protective role in several bacterial infectious
diseases. For example, while previous studies have established
that Listeria monocytogenes triggers autophagy, resulting in
reduced bacterial growth (Birmingham et al., 2007; Py et al.,
2007), in a listeriolysin O (LLO)-dependent manner (Meyer-
Morse et al., 2010), statin treatment was found to enhance
the host defense against L. monocytogenes by targeting LLO-
mediated phagosomal escape (Parihar et al., 2013). Furthermore,
it was recently reported that statin therapy protects against
Mycobacterium tuberculosis infection by enhancing autophagy
and promoting phagosome maturation (Parihar et al., 2014).
Consistent with these previous findings, our results demonstrate
that statin treatment promoted autophagosome maturation and
fusion with lysosomes, resulting in reduced bacterial burdens
within macrophages, and thereby mitigated pathogenic infection
by H. pylori (Figure 6).
There are several limitations to this study. First, only
RAW264.7 macrophages and PEMs were utilized in
our experiments; we have yet to test our findings in
FIGURE 6 | Model for the mechanism by which statin enhances autophagy and alleviates pathogenic infection by Helicobacter pylori. (A) Infected
macrophages harbor H. pylori, which inhibit phagosome maturation, within large vacuoles called megasomes. (B) Initiation of the autophagy pathway includes the
translocation of the ULK complex from the cytosol to the endoplasmic reticulum (ER) and recruitment of the PI3K complex, which triggers the initiation of phagophore
nucleation (Greenfield and Jones, 2013). This initiation process forms the isolation membranes, which in turn sequester cellular components and fuse to generate
autophagosomes. Treatment of cells with simvastatin promotes the fusion of autophagosomes with lysosomes, leading to reduction in bacterial burdens and
attenuation of H. pylori-induced inflammation.
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animal or human subjects. Likewise, the statin dosing
regimens used in our cell-based study have yet to be
evaluated in vivo. Therefore, further clinical investigations
are required to clarify the link between statin use and
regulation of autophagy. Such studies might pave the
way for developing new strategies to control H. pylori
infection.
In conclusion, the results of this investigation reveal that statin
could potentially be used to decrease the intracellular burden
of H. pylori in macrophages. In addition, statin enhanced early
endosome maturation and subsequent activation of autophagy
in macrophages, which promoted lysosomal fusion resulting
in the degradation of sequestered H. pylori, followed by
reductions in proinflammatory cytokine production. Future in
vivo investigations and treatment regimens are needed to study
the mechanism underlying the statin-mediated mitigation of H.
pylori infection.
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Figure S1 | Statin does not affect the phagocytotic activity of
macrophages. RAW264.7 cells treated with simvastatin (0 or 10µM) for 8 h were
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Figure S2 | Statin has no effect on extracellular bacterial adhesion to
macrophages. RAW264.7 cells untreated or treated with 10µM simvastatin for 8
h were infected with Helicobacter pylori (MOI = 100) for 6 h, washed three times
to remove unbound bacteria, and lysed by incubation in distilled water for 10 min.
Cell lysates were then plated onto Brucella blood agar plates and cultured for 3–5
days. The results are expressed as the mean (± standard deviation) number of
viable colony-forming units (CFU) obtained from three independent experiments.
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